Differences between reversible (self-association) and irreversible aggregation of rHuG-CSF in carbohydrate and polyol formulations

European Journal of Pharmaceutics and Biopharmaceutics

Volumn 76, Issue 3, 2010, Pages 357-365

  Pavišić, Renata ^a   Dodig, Ivana ^b   Horvatić, Anita ^b   Mijić, Lucija ^b   Sedić, Mirela ^b   Linarić, Maša Rajić ^c   Sovulj, Ita Gruić ^b   Preočanin, Tajana ^b   Krajačić, Mirjana Bukvić ^d   Cindrić, Mario ^b  

^a Hospira Zagreb doo   (Croatia)

^b UNIVERSITY OF ZAGREB   (Croatia)

^c PLIVA CROATIA LTD   (Croatia)

^d GLAXOSMITHKLINE   (United Kingdom)

Author keywords

Aggregation; Asymmetric field flow fractionation; RHuG CSF; Self association; Size exclusion chromatography; Stabiliser

Indexed keywords

CARBOHYDRATE; CELLOBIITOL; CELLOBIOSE; LACTITOL; LEUCROSE; LYXOSE; POLYOL; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; SORBITOL; TREHALOSE; TURANOSE; UNCLASSIFIED DRUG; XYLITOL;

ARTICLE; DIFFERENTIAL SCANNING CALORIMETRY; DRUG FORMULATION; FLUORESCENCE ANALYSIS; GEL PERMEATION CHROMATOGRAPHY; LIGHT SCATTERING; REFRACTION INDEX; THERMODYNAMICS; ULTRAVIOLET RADIATION;

CARBOHYDRATES; CHEMISTRY, PHARMACEUTICAL; EXCIPIENTS; FILGRASTIM; HUMANS; MODELS, THEORETICAL; POLYMERS; PROTEIN BINDING; PROTEIN CONFORMATION;

EID: 78549269071     PISSN: 09396411     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejpb.2010.09.006     Document Type: Article

References (31)

1. Ross C.A., Poirier M.A. Protein aggregation and neurodegenerative disease. Nat. Med. 2004, 10:S10-S17.
2. Cromwell M.E., Hilario E., Jacobson F. Protein aggregation and bioprocessing. AAPS J. 2006, 8:E572-E579.
3. Ratovitski T., Gucek M., Jiang H., Chighladze E., Waldron E., D'Ambola J., Hou Z., Liang Y., Poirier M.A., Hirschhorn R.R., Graham R., Hayden M.R., Cole R.N., Ross C.A. Mutant huntingtin N-terminal fragments of specific size mediate aggregation and toxicity in neuronal cells. J. Biol. Chem. 2009, 284:10855-10867.
4. Patro S.Y., Przybycien T.M. Simulations of reversible protein aggregate and crystal structure. Biophys. J. 1996, 70:2888-2902.
5. Chi E.Y., Krishnan S., Randolph T.W., Carpenter J.F. Physical stability of proteins in aqueous solution: mechanism and driving forces in nonnative protein aggregation. Pharm. Res. 2003, 20:1325-1336.
6. Pavišić R., Hock K., Mijić I., Horvatić A., Gecan M., Sedić M., Krajačić M.B., Cindrić M. Recombinant human granulocyte colony stimulating factor pre-screening and screening of stabilizing carbohydrates and polyols. Int. J. Pharm. 2010, 387:110-119.
7. Goyal M.K., Roy I., Banerjee U.C., Sharma V.K., Bansal A.K. Role of benzyl alcohol in the prevention of heat-induced aggregation and inactivation of hen egg white lysozyme. Eur. J. Pharm. Biopharm. 2009, 71:367-376.
8. He F., Hogan S., Latypov R.F., Narhi L.O., Razinkov V.I. High throughput thermostability screening of monoclonal antibody formulations. J. Pharm. Sci. 2010, 99:1707-1720.
9. Chang B.S., Hershenson S. Practical approaches to protein formulation development. Pharm. Biotechnol. 2002, 13:1-25.
10. Wang X., Das T.K., Singh S.K., Kumar S. Potential aggregation prone regions in biotherapeutics: a survey of commercial monoclonal antibodies. MAbs 2009, 1:254-267.
11. Ribarska J.T., Jolevska S.T., Panovska A.P., Dimitrovska A. Studying the formation of aggregates in recombinant human granulocyte-colony stimulating factor (rHuG-CSF), lenograstim, using size-exclusion chromatography and SDS-PAGE. Acta Pharm. 2008, 58:199-206.
12. Herman A.C., Boone T.C., Lu H.S. Characterization, formulation, and stability of Neupogen® (Filgrastim) a recombinant human granulocyte colony stimulating factor. Formulation, Characterisation and Stability of Protein Drugs 1996, 303-328. Plenum Press, New York. R. Pearlman, Y.J. Wang (Eds.).
13. Thirumangalathu R., Krishnan S., Brems D.N., Randolph T.W., Carpenter J.F. Effects of pH, temperature, and sucrose on benzyl alcohol-induced aggregation of recombinant human granulocyte colony stimulating factor. J. Pharm. Sci. 2006, 95:1480-1497.
14. Hill C.P., Osslund T.D., Eisenberg D. The structure of granulocyte-colony-stimulating factor and its relationship to other growth factors. Proc. Natl. Acad. Sci. USA. 1993, 90:5167-5171.
15. Wang W. Protein aggregation and its inhibition in biopharmaceutics. Int. J. Pharm. 2005, 289:1-30.
16. Vermeer A.W., Norde W. The thermal stability of immunoglobulin: unfolding and aggregation of a multi-domain protein. Biophys. J. 2000, 78:394-404.
17. Chen T., Oakley D.M. Thermal analysis of proteins of pharmaceutical interest. Thermochim. Acta 1995, 248:229-244.
18. Kendrick B.S., Cleland J.L., Lam X., Nguyen T., Randolph T.W., Manning M.C., Carpenter J.F. Aggregation of recombinant human interferon gamma: kinetics and structural transitions. J. Pharm. Sci. 1998, 87:1069-1076.
19. Cao X.-M., Yang X., Shi J.-Y., Liu Y.-W., Wang C.-X. The effect of glucose on bovine serum albumin denatured aggregation kinetics at high concentration: the master plots method study by DSC. J. Therm. Anal. Calorim. 2008, 93:451-458.
20. Sanchez-Ruiz J.M. Theoretical analysis of Lumry-Eyring models in differential scanning calorimetry. Biophys. J. 1992, 61:921-935.
21. Gottschalk M., Venu K., Halle B. Protein self-association in solution: the bovine pancreatic trypsin inhibitor decamer. Biophys. J. 2003, 84:3941-3958.
22. Wills P.R., Winzor D.J. Direct allowance for the effects of thermodynamic nonideality in the quantitative characterization of protein self-association by osmometry. Biophys. Chem. 2009, 145:64-71.
23. Gagnon P., Arakawa T. Aggregation detection and removal biopharmaceutical proteins. Curr. Pharm. Biotechnol. 2009, 10. 347-347.
24. Gabrielson J.P., Arthur K.K., Stoner M.R., Winn B.C., Kendrick B.S., Razinkov V., Svitel J., Jiang Y., Voelker P.J., Fernandes C.A., Ridgeway R. Precision of protein aggregation measurements by sedimentation velocity analytical ultracentrifugation in biopharmaceutical applications. Anal. Biochem. 2010, 396:231-241.
25. Liu J., Andya J.D., Shire S.J. A critical review of analytical ultracentrifugation and field flow fractionation methods for measuring protein aggregation. AAPS J. 2006, 8:E580-E589.
26. Sanchez-Ruiz J.M., Lopez-Lacomba J.L., Cortijo M., Mateo P.L. Differential scanning calorimetry of the irreversible thermal denaturation of thermolysin. Biochemistry 1988, 27:1648-1652.
27. Arakawa T., Philo J.S., Ejima D., Tsumoto K., Arisaka F. Aggregation analysis of therapeutic proteins, Part 1: general aspects and techniques for assessment. BioProcess Int. 2006, 4:42-43.
28. Arifin D.R., Palmer A.F. Determination of size distribution and encapsulation efficiency of liposome-encapsulated hemoglobin blood substitutes using asymmetric flow field-flow fractionation coupled with multi-angle static light scattering. Biotechnol. Prog. 2003, 19:1798-1811.
29. Li Y., Ogunnaike B.A., Roberts C.J. Multi-variate approach to global protein aggregation behavior and kinetics: effects of pH NaCl and temperature for alpha-chymotrypsinogen A. J. Pharm. Sci. 2010, 99:645-662.
30. Hinz H.J., Schwarz F.P. Measurement and analysis of results obtained on biological substances with differential scanning calorimetry. Pure Appl. Chem. 2001, 73:745-759.
31. Jimenez M., Rivas G., Minton A.P. Quantitative characterization of weak self-association in concentrated solutions of immunoglobulin G via the measurement of sedimentation equilibrium and osmotic pressure. Biochemistry 2007, 46:8373-8378.